Oral contraceptives and breast cancer risk overall and by molecular subtype among young women. 2014

Elisabeth F Beaber, and Kathleen E Malone, and Mei-Tzu Chen Tang, and William E Barlow, and Peggy L Porter, and Janet R Daling, and Christopher I Li
Authors' Affiliations: Division of Public Health Sciences, Division of Human Biology, Fred Hutchinson Cancer Research Center; Departments of Epidemiology, Biostatistics, and Pathology, University of Washington, Seattle, Washington.

BACKGROUND Evidence suggests that recent oral contraceptive (OC) use is associated with a small increased breast cancer risk; yet risks associated with contemporary OC preparations and by molecular subtype are not well characterized. METHODS We conducted a population-based case-control study of invasive breast cancer among women ages 20 to 44 residing in the Seattle-Puget Sound area from 2004 to 2010 (985 cases and 882 controls). We collected information on contraceptive use and participant characteristics via an in-person interview. Multivariable-adjusted logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CI). RESULTS Lifetime duration of OC use for ≥ 15 years was associated with an increased breast cancer risk (OR, 1.5; 95% CI, 1.1-2.2). Current OC use (within 1 year of reference date) for ≥ 5 years was associated with an increased risk (OR, 1.6; 95% CI, 1.1-2.5) and there were no statistically significant differences in risk by OC preparation. Risk magnitudes were generally greater among women ages 20 to 39, and for estrogen receptor-negative (ER(-)) and triple-negative breast cancer (current use for ≥ 5 years among ages 20-39: ER(-) OR, 3.5; 95% CI, 1.3-9.0; triple-negative OR, 3.7; 95% CI, 1.2-11.8), although differences between groups were not statistically significant. CONCLUSIONS Long-term use of contemporary OCs and current use for ≥ 5 years was associated with an increased breast cancer risk among women ages 20 to 44. Risk may be greater among younger women and for ER(-) and triple-negative breast cancer, but these findings require confirmation. CONCLUSIONS Continued surveillance and pooled analyses of OC use and breast cancer risk by molecular subtype are needed as OC preparations evolve.

UI MeSH Term Description Entries
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003276 Contraceptives, Oral Compounds, usually hormonal, taken orally in order to block ovulation and prevent the occurrence of pregnancy. The hormones are generally estrogen or progesterone or both. Low-Dose Oral Contraceptive,Oral Contraceptive,Oral Contraceptives,Oral Contraceptives, Low-Dose,Oral Contraceptives, Phasic,Contraceptive, Low-Dose Oral,Contraceptive, Oral,Contraceptives, Low-Dose Oral,Contraceptives, Phasic Oral,Low Dose Oral Contraceptive,Low-Dose Oral Contraceptives,Oral Contraceptive, Low-Dose,Oral Contraceptives, Low Dose,Phasic Oral Contraceptives
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor

Related Publications

Elisabeth F Beaber, and Kathleen E Malone, and Mei-Tzu Chen Tang, and William E Barlow, and Peggy L Porter, and Janet R Daling, and Christopher I Li
June 1995, Journal of the National Cancer Institute,
Elisabeth F Beaber, and Kathleen E Malone, and Mei-Tzu Chen Tang, and William E Barlow, and Peggy L Porter, and Janet R Daling, and Christopher I Li
January 2003, British journal of cancer,
Elisabeth F Beaber, and Kathleen E Malone, and Mei-Tzu Chen Tang, and William E Barlow, and Peggy L Porter, and Janet R Daling, and Christopher I Li
February 1986, Lancet (London, England),
Elisabeth F Beaber, and Kathleen E Malone, and Mei-Tzu Chen Tang, and William E Barlow, and Peggy L Porter, and Janet R Daling, and Christopher I Li
November 1985, Lancet (London, England),
Elisabeth F Beaber, and Kathleen E Malone, and Mei-Tzu Chen Tang, and William E Barlow, and Peggy L Porter, and Janet R Daling, and Christopher I Li
July 1998, Breast cancer research and treatment,
Elisabeth F Beaber, and Kathleen E Malone, and Mei-Tzu Chen Tang, and William E Barlow, and Peggy L Porter, and Janet R Daling, and Christopher I Li
December 2022, Breast (Edinburgh, Scotland),
Elisabeth F Beaber, and Kathleen E Malone, and Mei-Tzu Chen Tang, and William E Barlow, and Peggy L Porter, and Janet R Daling, and Christopher I Li
May 2022, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,
Elisabeth F Beaber, and Kathleen E Malone, and Mei-Tzu Chen Tang, and William E Barlow, and Peggy L Porter, and Janet R Daling, and Christopher I Li
January 1992, Cancer causes & control : CCC,
Elisabeth F Beaber, and Kathleen E Malone, and Mei-Tzu Chen Tang, and William E Barlow, and Peggy L Porter, and Janet R Daling, and Christopher I Li
June 2021, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,
Elisabeth F Beaber, and Kathleen E Malone, and Mei-Tzu Chen Tang, and William E Barlow, and Peggy L Porter, and Janet R Daling, and Christopher I Li
September 2001, Journal of the National Medical Association,
Copied contents to your clipboard!